Releases
DTIL
13.56
+4.47%
0.58
  • All
  • Financials
  • Insiders
More
Webull provides the latest Precision Biosciences (DTIL) stock and general news. This information may help you make smarter investment decisions.
About DTIL
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline comprises in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. ARCUS is a natural homing endonuclease which allows precise gene editing, such as gene insertions, gene excision, and gene elimination. ARCUS is also relatively small size which potentially allows delivery to a range of cells and tissues using viral and non-viral gene delivery methods. ARCUS uses sequence-specific deoxyribonucleic acid (DNA)-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues. The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-HbE, PBGENE-DMD, PBGENE-LLY2, PBGENE-LLY3, iECURE-OTC, and PBGENE-PMM. PBGENE-HBV is designed for the treatment of chronic hepatitis B virus (HBV).